SEAMLESS
LIVE

Serial Number

79402309

Owner

Seamless Therapeutics GmbH

Attorney

Brian J. Focarino

Filing Date

Dec 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SEAMLESS Trademark

Serial Number: 79402309 • Registration: 8172669

SEAMLESS is a trademark filed by Seamless Therapeutics GmbH on December 14, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Seamless Therapeutics GmbH (2 trademarks)

Tatzberg 47/49

Entity Type: 99

Trademark Details

Filing Date

December 14, 2023

Registration Date

March 17, 2026

Published for Opposition

January 27, 2026

Goods & Services

Chemicals for use in industry and science; biological preparations and biological chemical reagents for use in industry and science; all of the foregoing used for non-medical purposes

Pharmaceutical and biological preparations for gene therapies and gene-editing therapies, all for the treatment of genetic and viral diseases; medical, pharmaceutical and biopharmaceutical preparations and substances containing programmable recombinases for the treatment of genetic and viral diseases; pharmaceutical goods and preparations, namely, gene transfer, regulation, modulation and delivery medications for the treatment of genetic and viral diseases and disorders; products, agents, for medical purposes, for veterinary purposes in the nature of pharmaceutical preparations for cellular, genome and gene editing therapies to treat genetic, oncological, immune system-related, and inflammatory disorders and diseases; genome editable enzymes being enzymes for medical purposes; DNA recombinant enzymes being enzymes for medical purposes; DNA editable enzymes, especially, recombinases and integrases being enzymes for medical purposes; genome editable enzymes for the treatment of diseases being enzymes for medical purposes; DNA recombinant enzymes for the treatment of diseases being enzymes for medical purposes; DNA editable enzymes, in particular recombinases and integrases, for the treatment of diseases being enzymes for medical purposes

Scientific and technological services, namely, product research and testing of pharmaceuticals for cell and gene therapies in the field of pharmaceutical product development for the creation of bioinformatic algorithms and models; development of pharmaceutical preparations and medicines, none of the foregoing for diagnostics; pharmaceutical product development, none of the foregoing for diagnostics; pharmaceutical products development of genome editable enzymes for treatment and not diagnostic purposes; pharmaceutical products development of DNA editable enzymes, in particular recombinases and integrases, for treatment and not diagnostic purposes

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 19, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 19, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 19, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 19, 2026 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 17, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 17, 2026 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 29, 2026 OPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 27, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 27, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 21, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 14, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 14, 2026 OPNR
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 30, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 30, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 30, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 30, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 30, 2025 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Dec 30, 2025 ZZZX
EXPARTE APPEAL TERMINATED
Dec 22, 2025 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 22, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 22, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 22, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 22, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 22, 2025 CNEA
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Dec 22, 2025 JURT
NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Nov 10, 2025 GEA1
ACTION DENYING REQ FOR RECON E-MAILED
Nov 10, 2025 GECD
ACTION CONTINUING FINAL - COMPLETED
Nov 10, 2025 CNCF
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2025 CRFA
ASSIGNED TO LIE
Oct 27, 2025 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 20, 2025 ERFR
EX PARTE APPEAL-INSTITUTED
Oct 20, 2025 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Oct 20, 2025 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Oct 20, 2025 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 19, 2025 GNFN
FINAL REFUSAL E-MAILED
Apr 19, 2025 GNFR
FINAL REFUSAL WRITTEN
Apr 19, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 7, 2025 TROA
REFUSAL PROCESSED BY IB
Sep 30, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 7, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 7, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 4, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 3, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 22, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 21, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 21, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 15, 2024 REPR